The identification of new and more effective treatments for alcohol abuse remains a priority. Alcohol intake activates glucocorticoids, which have a key role in alcohol’s reinforcing properties. Glucocorticoid effects are modulated in part by the activity of 11β-hydroxysteroid dehydrogenases (11β-HSD) acting as pre-receptors. Here, we tested the effects on alcohol intake of the 11β-HSD inhibitor carbenoxolone (CBX, 18α-glycyrrhetinic acid 3β-O-hemisuccinate), which has been extensively used in the clinic for the treatment of gastritis and peptic ulcer and is active on both 11β-HSD1 and 11β-HSD2 isoforms. We observed that CBX reduces both baseline and excessive drinking in rats and mice. The CBX diastereomer 18α-glycyrrhetinic acid 3β-O-hemisuccinate (αCBX), which we found to be selective for 11β-HSD2, was also effective in reducing alcohol drinking in mice. Thus, 11β-HSD inhibitors may be a promising new class of candidate alcohol abuse medications, and existing 11β-HSD inhibitor drugs may be potentially re-purposed for alcohol abuse treatment.

Original Article
11β-hydroxysteroid dehydrogenase inhibition as a new potential therapeutic target for alcohol abuse

PP Sanna1, T Kawamura1, J Chen1, GF Koob2, AJ Roberts1, LF Vendruscolo3 and V Repunte-Canonigo1

INTRODUCTION
Alcohol remains the most prevalent abused substance in the United States, with an estimated 6.8 percent of the population aged 12 or older classified as having alcohol dependence or abuse.1 Few pharmacotherapies for alcohol abuse are currently available, and these have shown only limited efficacy and compliance.2–5 Thus, the development of more effective medications for alcohol abuse is a significant unmet medical need.5

Alcohol disrupts glucocorticoid regulation in both rodents7,8 and humans.9–13 Glucocorticoids have been implicated in alcohol’s reinforcing effects,14 and activation of glucocorticoids by alcohol is involved in the escalation of alcohol intake in dependent rats and alcohol-seeking and drinking during protracted abstinence.15,16 Both systemic and intracerebral glucocorticoid receptor antagonism with mifepristone blocked compulsive alcohol drinking in rats.13,15–17 In humans, high adrenal sensitivity (cortisol to corticotropin ratio) in response to stress was found to correlate with greater susceptibility to relapse to heavy drinking,12 whereas glucocorticoid receptor antagonist with mifepristone significantly reduced alcohol craving and drinking.13 The effects of glucocorticoids are modulated in target cells by the activity of 11β-hydroxysteroid dehydrogenase (11β-HSD) isozymes acting as pre-receptors that contribute to shape the tissue-specific responsiveness to glucocorticoids.18,19 In particular, 11β-HSD1, which is usually colocalized with the glucocorticoid receptor, converts 11-keto (inert) glucocorticoids such as cortisol in humans and 11β-dehydrocorticosterone in rodents, into 11-hydroxyl (active) glucocorticoids such as cortisol in humans and corticosterone in rodents, respectively, to enhance the effects of glucocorticoids.18,19 The reverse reaction by 11β-HSD2 attenuates local glucocorticoid responses in some mineralocorticoid receptor (MR)-expressing cells, such as classic aldosterone-selective target tissues (distal nephron, colon, sweat gland), although not in others, such as several MR-expressing brain regions.20 Given the role for glucocorticoids in mediating the reinforcing effects of alcohol,14,15 the relevance of 11β-HSD to the modulating effects of glucocorticoids on alcohol drinking is unknown.

Carbenoxolone (CBX, 3β-hydroxy-11-oxoolean-12-en-30-oic acid 3-hemisuccinate) is a derivative of glycyrrhetinic acid, a molecule present in licorice.18,19 CBX is a nonselective 11β-HSD inhibitor21 that has long been used for the treatment of gastritis and peptic ulcer.22 In addition to its modulatory role on glucocorticoid metabolism in target tissues, CBX also inhibits gap junctional communication, at potencies several orders of magnitude higher.23

Here we tested the hypothesis that CBX and its 18α diastereomer, 18α-glycyrrhetinic acid 3β-O-hemisuccinate (αCBX), would reduce alcohol intake in rodents because of their ability to modulate the actions of glucocorticoids. We show that these molecules are capable of reducing alcohol drinking in rodents in both baseline and excessive drinking models, and thus are promising new targets for the treatment of alcohol use disorder. We also show that αCBX is a selective inhibitor of 11β-HSD2 in the mouse.

MATERIALS AND METHODS
Drugs
CBX, 18α-glycyrrhetinic acid and 18β-glycyrrhetinic were purchased from Tocris (Bristol, UK); αCBX was custom synthesized from 18α-glycyrrhetinic acid (Tocris).

Subjects
Adult male Wistar rats (Charles River, Wilmington, MA, USA), weighing 225–275 g at the beginning of the experiments, were housed in groups of

1Department of Molecular and Cellular Neuroscience, The Scripps Research Institute, La Jolla, CA, USA; 2National Institute on Alcohol Abuse and Alcoholism, Rockville, MD, USA and 3Intramural Research Program, National Institute on Drug Abuse-National Institutes of Health, Baltimore, MD, USA. Correspondence: Dr PP Sanna, Department of Molecular and Cellular Neuroscience, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
E-mail: psanna@scripps.edu
Received 30 April 2015; revised 18 September 2015; accepted 8 November 2015
two to three per cage. Adult male C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME, USA) were housed four per cage except during drinking sessions. All the rodents were housed in a temperature-controlled (22 °C) vivarium on a 12 h/12 h light/dark cycle with ad libitum access to food and water except during behavioral testing. Operant and limited-access drinking tests were conducted during the dark phase of the light/dark cycle. All the procedures adhered to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of The Scripps Research Institute.

Rat operant self-administration
Self-administration sessions were conducted in standard operant conditioning chambers (Med Associates, St. Albans, VT, USA). The rats were trained to self-administer alcohol as previously reported. First, the rats were given free-choice access to alcohol (10% w/v) and water for 1 day in their home cages to habituate them to the taste of alcohol. Second, the rats were subjected to an overnight session in the operant chambers with access to one lever (right lever) that delivered water in a fixed-ratio 1 schedule where every lever press is reinforced with delivery of 0.1 ml of solution. Food was available ad libitum during this training. Third, after 1 day off, the rats were subjected to a 2 h session (fixed-ratio 1) for 1 day and a 1 h session (fixed-ratio 1) the next day, with one lever delivering alcohol (right lever). All the subsequent sessions lasted 30 min, and two levers were available (left lever: water; right lever: alcohol) until stable alcohol levels of intake were reached. Upon completion of this procedure, the animals were allowed to self-administer a 10% (w/v) alcohol solution and water on a fixed-ratio 1 schedule of reinforcement.

Rat alcohol vapor exposure
Rats were made dependent by chronic, intermittent exposure to alcohol vapors as previously described. They underwent cycles of 14 h on (blood alcohol levels during vapor exposure ranged between 150 and 250 mg%) and 10 h off, during which behavioral testing for acute withdrawal occurred (that is, 6–8 h after vapor was turned off when brain and blood alcohol levels are negligible). In this model, rats exhibit motivational and somatic withdrawal signs. Dependent rats were exposed to vapor for at least two months before testing. Non-dependent rats were placed in vapor chambers but were exposed to air for the purpose of control.

A separate cohort of rats was tested for self-administration of saccharin-sweetened water. We used a low saccharin concentration (0.004% w/v) based on previous studies to maintain approximately similar response rates as alcohol. Training for this experiment was identical to, and as described above, for alcohol, except that saccharin solution was used.

To investigate the effect of CBX on alcohol self-administration, we tested rats trained to self-administer alcohol with and without a history of alcohol vapor exposure sufficient to induce dependence and increased alcohol intake. CBX was administered acutely intraperitoneally in saline 90 min before testing at doses of 0, 20 and 40 mg kg⁻¹, which are in line with the scientific literature.

Mouse two-bottle choice and chronic intermittent ethanol exposure
To evaluate the effects of CBX on drinking in nondependent and dependent mice, we used the chronic intermittent ethanol exposure paradigm. C57BL/6J mice had access to two bottles, one containing water and the other containing 15% (v/v) ethanol, for 2 h starting 0.5 h before onset of the dark phase. Following acquisition of stable alcohol intake, half of the mice were subjected to repeated bouts of ethanol vapor exposure consisting of 16 h per day for 4 days. Before each exposure to ethanol vapor, mice were intra-peritoneally injected with a solution of 1.5 g kg⁻¹ ethanol and 68.1 mg kg⁻¹ pyrazole and immediately placed into ethanol vapor chambers (La Jolla Alcohol Research, La Jolla, CA, USA). Tail blood sampling for blood ethanol level determination was carried out every other day. Target blood ethanol levels were 175–250 mg%. Seventy-two hours following removal from the chambers, mice received access to water vs 15% (v/v) ethanol for 2 h, and again over the next 4 days. The following week, the mice were re-exposed to the ethanol vapor/control conditions and again tested for two-bottle choice drinking for 5 days. Three vapor bouts followed by two-bottle choice were carried out. Mice were weighed every 4–6 days throughout the two-bottle choice sessions and daily during the vapor exposure bouts. Food and water were available ad libitum and the mice were group housed except during the ethanol drinking sessions.

Mouse drinking in the dark
To evaluate the effects of CBX on binge-like drinking, mice were tested in the drinking-in-the-dark (DID) paradigm. The DID paradigm capitalizes on the circadian rhythm in drinking of mice utilizing a discrete time of exposure to ethanol to obtain pharmacologically significant ethanol drinking in a 4-day procedure. Blood alcohol levels of C57BL/6J mice in DID are reliably over 100 mg dl⁻¹ following the final drinking bout and produce behavioral intoxication. In the DID procedure, the water bottle is replaced with a bottle containing 20% (v/v) ethanol for 2 h in the home cage 3 h after lights go off. The design involves three daily drinking sessions of 2 h and a fourth of 4 h. The effects of CBX and αCBX were tested in the fourth, 4 h session. Compounds were administered acutely intraperitoneally 90 min before testing at doses of 0, 20 and 40 mg kg⁻¹.

11β-HSD activity
11β-HSD1 and 11β-HSD2 activities were measured by homogeneous time-resolved fluorescence assays, conducted by SB Drug Discovery (Glasgow, UK) using recombinant human and mouse 11β-HSD1 and 11β-HSD2.

RESULTS
We first tested the effect of CBX on nondependent and dependent alcohol drinking in rats. An established strategy was used to induce alcohol dependence through chronic exposure to intermittent alcohol vapors. Alcohol-dependent rats, as in previous studies, showed increased lever press responding for alcohol compared with nondependent rats (Figure 1a; group effect: F₁,₁₇ = 32.9; P < 0.0001). Acute intraperitoneal administration of CBX 90 min before testing dose-dependently reduced responding for alcohol in both dependent and nondependent rats (Figure 1a; dose effect: F₂,₃₄ = 5.0; P < 0.05). No significant effects of CBX were found for water responding (Figure 1b; dose effect: F₂,₃₄ = 0.23; P = 0.80) or in self-administration of saccharin-sweetened water (Figures 1c; F₁,₁₈ = 0.83; P = 0.42). Note that responding levels for saccharine are equivalent to those for alcohol in the dependent group.

We then tested CBX in nondependent mice in a limited-access two-bottle choice paradigm as well as in mice subjected to repeated bouts of ethanol vapors to induce dependence. CBX decreased alcohol intake more effectively in nondependent than in dependent mice at a dose of 40 mg kg⁻¹ (Figure 2). Because 18α-glycyrrhetinic acid has been reported to be a selective inhibitor of human 11β-HSD1, we also synthesized αCBX, the 18α diastereomer of CBX (18α-glycyrrhetinic acid 3β-O-hemisuccinate), to explore its potential isozyme selectivity. We observed that 18α-glycyrrhetinic acid and 18β-glycyrrhetinic acid are active both on mouse and human 11β-HSD1 and 11β-HSD2 isoforms.
observed that CBX reduced drinking in the DID paradigm at both 20 and 40 mg kg\(^{-1}\) (Figures 5a and b). aCBX showed similar potency as CBX in reducing drinking in the DID paradigm in mice (Figures 5c and d). As 11β-HSD2 in the kidney contributes to blood pressure regulation, we tested the effects of CBX and aCBX and found that neither compound affected blood pressure in mice (Table 1), consistent with the results of previous studies with CBX in both mice and rats.\(^{40,41}\)

**DISCUSSION**

Only a limited number of drugs exist with clinical efficacy for the treatment of alcohol abuse.\(^{6,42}\) Expansion of therapeutic options is needed to improve treatment success at different stages of disease progression and to bring about individualized therapies based on patient genetic makeup.\(^{6,42}\)

Glucocorticoids facilitate drug seeking, brain stimulation reward, dopamine release and are themselves self-administered.\(^{43,44}\) The present effects of CBX in reducing alcohol intake could be related to the facilitation of reward mechanisms associated with activation of glucocorticoids.\(^{14,43,45}\) The present results show that the unselective 11β-HSD inhibitor CBX effectively reduces alcohol intake in both dependent and nondependent rats and mice. This suggests that 11β-HSDs may have a fundamental role in modulating the reinforcing effects of alcohol via their actions in modulating glucocorticoids, and that existing 11β-HSD inhibitor drugs, such as CBX as well as others, for example, see refs 46,47, can potentially be re-purposed for alcohol abuse. Re-purposing of drugs with known safety profiles in humans for diseases other than the ones for which they were originally developed is a potentially fast and effective way to address an unmet medical need.\(^{48}\)

Glucocorticoid receptors in multiple brain regions have been implicated in the effects of alcohol.\(^{15}\) 11β-HSD1 is broadly expressed in the adult rat brain, including in brain regions relevant to alcohol reinforcing properties such as the amygdala.\(^{19-51}\) Thus, the previously shown ability of CBX to inhibit central 11β-HSD1,\(^{52,53}\) resulting in reduced glucocorticoid signaling, likely contributes to reduced drinking, paralleling the effects of the glucocorticoid receptor inhibitor mifepristone on drinking.\(^{15,16}\) The comparable effects in the mouse of CBX, which inhibits both 11β-HSD isozymes, and aCBX, a selective 11β-HSD2 inhibitor in the mouse, point to a potential role also for the latter isozyme in alcohol drinking. In the brain, 11β-HSD2 is expressed primarily in a subpopulation of neurons in the nucleus tractus solitarius.\(^{54-56}\) This neuronal population, denominated HSD2 neurons, receive inputs from the central nucleus of the amygdala and paraventricular nucleus of the hypothalamus, and project to the ventral BNST, polysynaptically to the nucleus accumbens, and both directly and indirectly to the central nucleus of the amygdala.\(^{54,57,58}\) Locally, HSD2 neurons are targeted by a group of neurons in the dorsomedial nucleus tractus solitarii that express neurotensin,\(^{59}\) which has been implicated in the regulation of alcohol intake.\(^{60}\) Thus, the connectivity of HSD2 neurons in the nucleus tractus solitarii suggests that inhibition of 11β-HSD2 in this neuronal population may result in central effects on alcohol intake. Future studies are needed to explore the relative contributions of 11β-HSD isozymes to alcohol drinking, as well as the contribution of 11β-HSD to the phenotype of genetic models of excessive alcohol drinking, such as alcohol-preferring rodents differing in their glucocorticoid regulation.\(^{61,62}\)

11β-HSD1 inhibitors are being considered as potential cognitive enhancers, as well as for the therapy of type 2 diabetes, metabolic syndrome and obesity.\(^{53,63}\) 11β-HSD1 knockout mice show resistance to diet-induced obesity, increased glucose tolerance and insulin sensitivity.\(^{63}\) In addition, studies with 11β-HSD1 null mice and 11β-HSD1-selective inhibitors indicate a role for 11β-HSD1 in the intake of palatable food,\(^{64}\) but the mechanism behind

---

**Figure 1.** CBX reduces ethanol intake in rats in an operant self-administration paradigm. (a) Acute, systemic administration of CBX decreases operant alcohol self-administration both in dependent (dep) and nondependent (nondep) rats. (b) CBX did not influence water intake in any group. (c) Acute, systemic administration of CBX does not affect operant self-administration of saccharin-sweetened water. Rats were given CBX (0, 20 and 40 mg kg\(^{-1}\) or 0 and 40 mg kg\(^{-1}\); intraperitoneally) 90 min before alcohol (10%, w/v), water or saccharin (0.004%) self-administration (30 min session; fixed-ratio 1). The data represent means and s.e.m. *P < 0.05, significant difference from respective vehicle; **P < 0.01, significant difference from vehicle (saline)-treated nondependent rats. N = 9–10 per group.

**Figure 2.** CBX reduces ethanol intake in nondependent (nondep) and dependent (dep) mice in a limited-access two-bottle choice paradigm. The mice trained to drink alcohol in a limited-access (2 h) two-bottle choice paradigm were either exposed to alcohol vapor to induce dependence or air for the purpose of control, and tested for the effect of CBX on drinking. CBX reduced ethanol intake in nondependent mice at doses of 20 and 40 mg kg\(^{-1}\) intraperitoneally (left), and in dependent mice at 40 mg kg\(^{-1}\) intraperitoneally (right). The two-way analysis of variance revealed a significant effect of vapor exposure (F\(_{2,35} = 33.38, P < 0.0001\)), dose (F\(_{2,35} = 13.04, P < 0.0001\)) and interaction of vapor exposure and dose (F\(_{2,35} = 3.902, P = 0.0295\)). *P < 0.05, **P < 0.01 and ***P < 0.001 represent significant difference from the respective vehicle (saline)-treated group; "P < 0.01 and """P < 0.001 represent significant difference from the respective nondependent group.

(Figure 3), whereas aCBX proved to be a selective inhibitor of mouse 11β-HSD2 with comparable, although slightly lower, potency on mouse HSD2 than CBX (Figure 4).

We then tested the effects of CBX and aCBX in the ‘drinking in the dark’ (DID) paradigm of binge-like drinking in mice.\(^{25}\) We...
Figure 3. Activity of 18α-glycyrrhetinic acid and 18β-glycyrrhetinic on mouse and human 11β-HSD1 and 11β-HSD2. We tested the IC50 of α- and β-glycyrrhetinic acid (GA) against human and mouse 11β-HSD1 and 11β-HSD2 by means of homogeneous time-resolved fluorescence (HTRF) assays. (a) and (c) α-GA yielded IC50 values of 532.1 nM for human 11β-HSD1 and 6.63 μM for mouse 11β-HSD1. (b and d) α – GA yielded IC50 values of 942.6 nM for human 11β-HSD2 and 159.7 nM for mouse 11β-HSD2. (e and g) β – GA yielded IC50 values of 232.3 nM for human 11β-HSD1 and 5.85 μM for mouse 11β-HSD1. (f and h) β – GA yielded IC50 values of 674.5 nM for human 11β-HSD2 and 79.7 nM for mouse 11β-HSD2.

Figure 4. Activity of carbenoxolone (CBX, 18β-glycyrrhetinic acid 3β-O-hemisuccinate) and αCBX (18α-glycyrrhetinic acid 3β-O-hemisuccinate) on mouse and human 11β-HSD1 and 11β-HSD2. We tested the IC50 of 18α – 18β-glycyrrhetinic acid 3β-O-hemisuccinate against human and mouse 11β-HSD1 and 11β-HSD2 by means of homogeneous time-resolved fluorescence (HTRF) assays. (a and c) CBX yielded IC50 values of 753.1 nM for human 11β-HSD1 and 4.62 μM for mouse 11β-HSD1. (b and d) CBX yielded IC50 values of 379.6 nM for human 11β-HSD2 and 628.7 nM for mouse 11β-HSD2. (e and g) αCBX yielded IC50 values of 15.92 μM for human 11β-HSD1 and 48.25 μM for mouse 11β-HSD1. (f and h) αCBX yielded IC50 values of 30.67 μM for human 11β-HSD2 and 1.06 μM for mouse 11β-HSD2. Results for CBX are the average of two to three independent replicates; results for αCBX are the average of three to four independent replicates.
CBX, which inhibits both 11β-HSD isoforms, has long been used in the clinic for the therapy of gastritis and peptic and duodenal ulcers. However, its use has greatly diminished in favor of other classes of drugs, such as proton pump inhibitors and histamine H2 antagonists. This is in part because of the potential of chronic CBX use to induce pseudohyperaldosteronism, which is due to inhibition by CBX of 11β-HSD type 2 isom (11β-HSD2) in the kidney. By inactivating glucocorticoids in the kidney and other mineralocorticoid target tissues, 11β-HSD2 shields the mineralocorticoid receptor from activation by glucocorticoids. Thus, inhibition of 11β-HSD2 permits glucocorticoids to act on mineralocorticoid receptors. However, this side effect can be managed by combination with an anti-kaliuretic diuretic, such as amiloride, or thiazide diuretics and potassium supplementation.

The development of new and more effective medications for alcoholism remains a priority. Here we showed that CBX and its diastereomer αCBX, which is a selective inhibitor of mouse 11β-HSD2, reduce baseline and excessive drinking in rodents. Collectively, the present results suggest that 11β-HSD inhibitors may represent a promising new class of candidate therapeutic targets to treat alcohol use disorders.

CONFLICT OF INTEREST

PPS is an inventor on a related patent application. The remaining authors declare no conflict of interest.

ACKNOWLEDGMENTS

This work was supported by NIH grants AA020960, AA021667, AA017371 and AA020893 and by the National Institute on Drug Abuse Intramural Research Program (LFP).

REFERENCES

1. SAMHSA. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Substance Abuse and Mental Health Services Administration: Rockville, MD, USA, 2013.
2. Berrettini W. Opioid pharmacogenetics of alcohol addiction. Cold Spring Harb Perspect Med 2013; 3: a012023.
3. Mason BJ, Quello S, Goodell V, Shadah F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med 2014; 174: 70–77.
4. Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res 2012; 36: 497–508.
5. Goldman D, Oroszi G, O'Malley S, Anton R. COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms. J Stud Alcohol Suppl 2005; 15: 56–64.
6. Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML et al. Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol 2012; 17: 513–527.
7. Richardson HN, Lee SY, O’Dell LE, Koob GF, Rivier CL. Alcohol self-administration acutely stimulates the hypothalamic-pituitary-adrenal axis, but alcohol dependence leads to a dampened neuroendocrine state. Eur J Neurosci 2008; 28: 1641–1653.
8. Rasmussen DD, Boldt BM, Bryant CA, Mitton DR, Larsen SA, Wilkinson CW. Chronic daily ethanol and withdrawal: 1. Long-term changes in the hypothalamo-pituitary-adrenal axis. Alcohol Clin Exp Res 2000; 24: 1836–1849.
9. Adinoff B, Rutherford K, Krebsa M, Imanashen E, Williams MJ. Increased salivary cortisol concentrations during chronic alcohol intoxication in a naturalistic clinical sample of men. Alcohol Clin Exp Res 2003; 27: 1420–1427.
10. Lovato WR, Dickensheets SL, Myers DA, Thomas TL, Nixon SJ. Blunted stress cortisol response in abstinent alcoholic and polysubstance-abusing men. Alcohol Clin Exp Res 2000; 24: 651–658.
11. Uhart M, Wand GS. Stress, alcohol and drug interaction: an update of human research. Addict Biol 2009; 14: 43–64.
12. Sinha R, Fox HC, Hong KL, Hansen J, Tutt K, Kreek MJ. Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes. Arch Gen Psychiatry 2011; 68: 942–952.
13. Vendruscolo LF, Estey D, Goodell V, Machshne LG, Logrip ML, Schlosburg JE et al. Glucocorticoid receptor antagonist decreases alcohol seeking in alcohol-dependent individuals. J Clin Invest 2015; 125: 3193–3197.

14. Fahlke C, Hard E, Eriksson CJ, Engel JA, Hansen S. Consequence of long-term exposure to corticosterone or dexamethasone on ethanol consumption in the adrenalectomized rat, and the effect of type I and type II corticosteroid receptor antagonists. Psychopharmacology 2002; 164: 68.

15. Vendruscolo LF, Barbier E, Schlosburg JE, Misra KK, Whitfield TW Jr., Logrip ML et al. Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats. J Neurosci 2012; 32: 7563–7571.

16. Repunte-Canonigo V, Shin W, Vendruscolo LF, Lefebvre C, Koob GF, Califano A et al. Identifying candidate drivers of alcohol dependence-induced excessive drinking by assembly and interrogation of brain-specific regulatory networks. Genome Biol 2015; 16: 49.

17. Edwards S, Vendruscolo LF, Schlosburg JE, Misra KK, Wee S, Park PE et al. Development of mechanical hypersensitivity in rats during heroin and ethanol dependence: alleviation by CRF(1) receptor antagonism. Neuropharmacology 2012; 62: 1142–1151.

18. Chapman K, Holmes M, Seckl J. 11beta-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev 2013; 93: 1139–1206.

19. Draper N, Stewart PM. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 2005; 186: 251–271.

20. Albiston AL, Obeyssekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994; 105: 811–817.

21. Stewart PM, Wallace AM, Atherden SM, Shearing CH, Edwards CR. Miner- alocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and licorice on 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Sci (Lond) 1990; 78: 49–54.

22. Bertacini G, Coruzzi G. Pharmacology of the treatment of peptic ulcer disease. Dig Dis Sci 1985; 30(11 Suppl): 435–515.

23. Andrews RC, Rooyackers O, Walker BR. Effects of the 11 beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 285–291.

24. Gilpin NW, Smith AD, Cole M, Weiss F, Koob GF, Richardson HN. Operant behavior and alcohol levels in blood and brain of alcohol-dependent rats. Alcohol Clin Exp Res 2009; 33: 2113–2123.

25. Rimondini R, Sommer W, Heilig M. A temporal threshold for induction of persistent alcohol preference: behavioral evidence in a rat model of intermittent intoxication. J Stud Alcohol 2003; 64: 445–449.

26. Roberts AJ, Heyser CJ, Cole M, Griffin P, Koob GF. Excessive ethanol drinking following a history of dependence: animal model of allostasis. Neuropsychopharmacology 2000; 22: 581–594.

27. Prasad Sakamuri SS, Sukapaka M, Prathapitiyake VK, Nemanl H, Putcha UK, Pothana S et al. Carbenoxolone treatment ameliorated metabolic syndrome in WNN/Ob obese rats, but induced severe fat loss and glucose intolerance in lean rats. PLoS One 2012; 7: e50216.

28. Beraki S, Litrus L, Soriano L, Monbureau M, To LK, Braithwaite SP. Identification of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. Am J Physiol Endocrinol Metab 2007; 293: E1517–E1528.

29. Lindsay RS, Lindsay RM, Edwards CR, Seckl JR. Inhibition of 11beta-hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring. Hypertension 1996; 27: 1200–1204.

30. Heilig M, Goldman DB, Berrettini W, O’Brien CP. Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 2011; 12: 670–684.

31. Piazza PV, Le Moal M. The role of stress in drug self-administration. Trends Pharmacol Sci 1998; 19: 67–74.

32. Deroche V, Piazza PV, Demineiri JM, Le Moal M, Simon H. Rats orally self-administer corticosterone. Brain Res 1993; 622: 315–320.

33. Lu YL, Richardson HN. Alcohol, stress hormones, and the prefrontal cortex: a proposed pathway to the dark side of addiction. Neuroscience 2014; 277: 139–151.

34. Penning TM. Human hydroxysteroid dehydrogenases and pre-receptor regulation: insights into inhibitor design and evaluation. J Steroid Biochem Mol Biol 2011; 125: 46–56.

35. Van SC, Goldberg FW, Turnbull AV. Medicinal chemistry of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). J Med Chem 2014; 57: 4466–4486.

36. Stittsmatter SM. Overcoming drug development bottlenecks with repurposing: old drugs learn new tricks. Nat Med 2014; 20: 590–591.

37. Pelletier G, Luu-The V, Li S, Bujold G, Labrie F. Localization and glucocorticoid regulation of 11beta-hydroxysteroid dehydrogenase type 1 mRNA in the male mouse forebrain. Neuroscience 2007; 145: 110–115.

38. Kanitz E, Puppe B, Tuschcherer M, Heberer M, Viergutz T, Tuschcherer A. A single exposure to social isolation in domestic piglets activates behavioural arousal, neuroendocrine stress hormones, and stress-related gene expression in the brain. Physiol Behav 2009; 98: 176–185.

39. Ons SG, Chng K, Meaney MJ, Buschdorf JP. Decreased hippocampal mineralocorticoid/glucocorticoid receptor ratio is associated with low birth weight in female cynomolgus macaque neonates. J Mol Endocrinol 2013; 51: 59–67.

40. Jellinck PH, Monder C, McEwen BS, Sakai RR. Differential inhibition of 11 beta-hydroxysteroid dehydrogenase by carbenoxolone in rat brain regions and peripheral tissues. J Steroid Biochem Mol Biol 1993; 46: 209–213.

41. Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, Walker BR et al. Aldosterone-sensitive neurons in the rat central solitary tract: bidirectional connections with the central nucleus of the amygdala. J Comp Neurol 1994; 330: 494–527.

42. Sequeira SM, Geerling JC, Loewy AD. Local inputs to aldosterone-sensitive neurons of the hippocampus. Brain Res 2009; 1262: 167–171.

43. Piazza PV, Le Moal M. The role of stress in drug self-administration. Trends Pharmacol Sci 1998; 19: 67–74.

44. Lindsay RS, Lindsay RM, Edwards CR, Seckl JR. Inhibition of 11beta-hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring. Hypertension 1996; 27: 1200–1204.

45. Heilig M, Goldman DB, Berrettini W, O’Brien CP. Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 2011; 12: 670–684.

46. Piazza PV, Le Moal M. The role of stress in drug self-administration. Trends Pharmacol Sci 1998; 19: 67–74.

47. Pelletier G, Luu-The V, Li S, Bujold G, Labrie F. Localization and glucocorticoid regulation of 11beta-hydroxysteroid dehydrogenase type 1 mRNA in the male mouse forebrain. Neuroscience 2007; 145: 110–115.

48. Kanitz E, Puppe B, Tuschcherer M, Heberer M, Viergutz T, Tuschcherer A. A single exposure to social isolation in domestic piglets activates behavioural arousal, neuroendocrine stress hormones, and stress-related gene expression in the brain. Physiol Behav 2009; 98: 176–185.

49. Ons SG, Chng K, Meaney MJ, Buschdorf JP. Decreased hippocampal mineralocorticoid/glucocorticoid receptor ratio is associated with low birth weight in female cynomolgus macaque neonates. J Mol Endocrinol 2013; 51: 59–67.

50. Jellinck PH, Monder C, McEwen BS, Sakai RR. Differential inhibition of 11 beta-hydroxysteroid dehydrogenase by carbenoxolone in rat brain regions and peripheral tissues. J Steroid Biochem Mol Biol 1993; 46: 209–213.

51. Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, Walker BR et al. Aldosterone-sensitive neurons in the rat central solitary tract: bidirectional connections with the central nucleus of the amygdala. J Comp Neurol 1994; 330: 494–527.

52. Sequeira SM, Geerling JC, Loewy AD. Local inputs to aldosterone-sensitive neurons of the hippocampus. Brain Res 2009; 1262: 167–171.

53. Piazza PV, Le Moal M. The role of stress in drug self-administration. Trends Pharmacol Sci 1998; 19: 67–74.

54. Lindsay RS, Lindsay RM, Edwards CR, Seckl JR. Inhibition of 11beta-hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring. Hypertension 1996; 27: 1200–1204.

55. Heilig M, Goldman DB, Berrettini W, O’Brien CP. Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 2011; 12: 670–684.
63 Gathercole LL, Stewart PM. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. *J Steroid Biochem Mol Biol* 2010; **122**:21–27.

64 Wang SJ, Birtles S, de Schoolmeester J, Swales J, Moody G, Hislop D et al. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. *Diabetologia* 2006; **49**:1333–1337.

65 Hamo E, Cottrell EC, Yu A, DeSchoolmeester J, Gutierrez PM, Denn M et al. 11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors still improve metabolic phenotype in male 11beta-HSD1 knockout mice suggesting off-target mechanisms. *Endocrinology* 2013; **154**:4580–4593.

66 Giardino WJ, Ryabinin AE. CRF1 receptor signaling regulates food and fluid intake in the drinking-in-the-dark model of binge alcohol consumption. *Alcohol Clin Exp Res* 2013; **37**:1161–1170.

67 Richardson HN, Zhao Y, Fekete EM, Funk CK, Wirsching P, Janda KD et al. MPZP: a novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist. *Pharmacol Biochem Behav* 2008; **88**:497–510.

68 Funk CK, Zorrilla EP, Lee MJ, Rice KC, Koob GF. Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. *Biol Psychiatry* 2007; **61**:78–86.

69 Pinder RM, Brogden RN, Sawyer PR, Speight TM, Spencer R, Avery GS. Carbenoxolone: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease. *Drugs* 1976; **11**:245–307.

70 Turpie AG, Runcie J, Thomson TJ. Clinical trial of deglycyrrhizinized liquorice in gastric ulcer. *Gut* 1969; **10**:299–302.

71 Turpie AG, Thomson TJ. Carbenoxolone sodium in the treatment of gastric ulcer with special reference to side-effects. *Gut* 1965; **6**:591–594.

72 Schenk J, Schmack B, Rosch W, Domschke W. Controlled trial of carbenoxolone sodium vs cimetidine in duodenal ulcer. *Scand J Gastroenterol Suppl* 1980; **65**:103–107.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/